Il dupilumab nell’esofagite eosinofila: una nuova frontiera?
Medico e Bambino(2022)
Abstract
Eosinophilic oesophagitis (EoE) is a chronic, immune-mediated or antigen-mediated oe-sophageal disease. Therapeutic first-line options currently available for EoE are elimina-tion diets, proton pump inhibitors (PPIs) and steroids. The ultimate goal of the therapy is to avoid irreversible stricturing disease. Despite the rising prevalence of EoE, there has been little therapeutic advancement until recently. Dupilumab is one of the potential disease-modifying biologics used in various stages of clinical trials. The paper describes the case of a 10-year-old boy presenting with sub-oesophageal stricture in eosinophilic oesophagitis and steroid-dependence for disease control who was successfully treated with dupilumab.
MoreTranslated text
AI Read Science
Must-Reading Tree
Example
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined